435 related articles for article (PubMed ID: 34959151)
1. Identification of potent food constituents as SARS-CoV-2 papain-like protease modulators through advanced pharmacoinformatics approaches.
Bhowmick S; Saha A; AlFaris NA; ALTamimi JZ; ALOthman ZA; Aldayel TS; Wabaidur SM; Islam MA
J Mol Graph Model; 2022 Mar; 111():108113. PubMed ID: 34959151
[TBL] [Abstract][Full Text] [Related]
2. Identification of bio-active food compounds as potential SARS-CoV-2 PLpro inhibitors-modulators via negative image-based screening and computational simulations.
Bhowmick S; AlFaris NA; Zaidan ALTamimi J; ALOthman ZA; Patil PC; Aldayel TS; Wabaidur SM; Saha A
Comput Biol Med; 2022 Jun; 145():105474. PubMed ID: 35395517
[TBL] [Abstract][Full Text] [Related]
3. Molecular modelling on SARS-CoV-2 papain-like protease: an integrated study with homology modelling, molecular docking, and molecular dynamics simulations.
Arwansyah A; Arif AR; Ramli I; Kurniawan I; Sukarti S; Nur Alam M; Illing I; Farid Lewa A; Manguntungi B
SAR QSAR Environ Res; 2021 Sep; 32(9):699-718. PubMed ID: 34392751
[TBL] [Abstract][Full Text] [Related]
4. Microbial based natural compounds as potential inhibitors for SARS-CoV-2 Papain-like protease (PLpro): a molecular docking and dynamic simulation study.
Rahul S; Sarkar A
J Biomol Struct Dyn; 2022; 40(24):13848-13858. PubMed ID: 34730069
[TBL] [Abstract][Full Text] [Related]
5. Computational investigation of binding of chloroquinone and hydroxychloroquinone against PLPro of SARS-CoV-2.
Patel D; Athar M; Jha PC
J Biomol Struct Dyn; 2022 Apr; 40(7):3071-3081. PubMed ID: 33200683
[TBL] [Abstract][Full Text] [Related]
6. Promising antivirals for PLpro of SARS-CoV-2 using virtual screening, molecular docking, dynamics, and MMPBSA.
Kumari R; Kumar V; Dhankhar P; Dalal V
J Biomol Struct Dyn; 2023 Jul; 41(10):4650-4666. PubMed ID: 35510600
[TBL] [Abstract][Full Text] [Related]
7. A computational essential dynamics approach to investigate structural influences of ligand binding on Papain like protease from SARS-CoV-2.
Singh E; Jha RK; Khan RJ; Kumar A; Jain M; Muthukumaran J; Singh AK
Comput Biol Chem; 2022 Aug; 99():107721. PubMed ID: 35835027
[TBL] [Abstract][Full Text] [Related]
8.
Rudrapal M; Issahaku AR; Agoni C; Bendale AR; Nagar A; Soliman MES; Lokwani D
J Biomol Struct Dyn; 2022; 40(20):10437-10453. PubMed ID: 34182889
[TBL] [Abstract][Full Text] [Related]
9. Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study.
Gogoi M; Borkotoky M; Borchetia S; Chowdhury P; Mahanta S; Barooah AK
J Biomol Struct Dyn; 2022 Sep; 40(15):7143-7166. PubMed ID: 33715595
[TBL] [Abstract][Full Text] [Related]
10. Molecular docking studies, molecular dynamics and ADME/tox reveal therapeutic potentials of STOCK1N-69160 against papain-like protease of SARS-CoV-2.
Elekofehinti OO; Iwaloye O; Josiah SS; Lawal AO; Akinjiyan MO; Ariyo EO
Mol Divers; 2021 Aug; 25(3):1761-1773. PubMed ID: 33201386
[TBL] [Abstract][Full Text] [Related]
11. Structure-Based Screening to Discover New Inhibitors for Papain-like Proteinase of SARS-CoV-2: An
Jamalan M; Barzegari E; Gholami-Borujeni F
J Proteome Res; 2021 Jan; 20(1):1015-1026. PubMed ID: 33350309
[TBL] [Abstract][Full Text] [Related]
12. Computational Evidences of Phytochemical Mediated Disruption of PLpro Driven Replication of SARS-CoV-2: A Therapeutic Approach against COVID-19.
Balkrishna A; Mittal R; Arya V
Curr Pharm Biotechnol; 2021; 22(10):1350-1359. PubMed ID: 33176643
[TBL] [Abstract][Full Text] [Related]
13. Ciclesonide Inhibits SARS-CoV-2 Papain-Like Protease in Vitro.
Kiba Y; Tanikawa T; Kitamura M
Biol Pharm Bull; 2024; 47(5):965-966. PubMed ID: 38763750
[TBL] [Abstract][Full Text] [Related]
14. Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease.
Liu W; Wang J; Wang S; Yue K; Hu Y; Liu X; Wang L; Wan S; Xu X
Bioorg Chem; 2023 Nov; 140():106830. PubMed ID: 37683544
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations.
Tumskiy RS; Tumskaia AV; Klochkova IN; Richardson RJ
Comput Biol Med; 2023 Feb; 153():106449. PubMed ID: 36586228
[TBL] [Abstract][Full Text] [Related]
16. Molecular docking and simulation studies of natural compounds of
Mitra D; Verma D; Mahakur B; Kamboj A; Srivastava R; Gupta S; Pandey A; Arora B; Pant K; Panneerselvam P; Ghosh A; Barik DP; Mohapatra PKD
J Biomol Struct Dyn; 2022 Aug; 40(12):5665-5686. PubMed ID: 33459176
[TBL] [Abstract][Full Text] [Related]
17. Identification of SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors Using Combined Computational Approach.
Sencanski M; Perovic V; Milicevic J; Todorovic T; Prodanovic R; Veljkovic V; Paessler S; Glisic S
ChemistryOpen; 2022 Feb; 11(2):e202100248. PubMed ID: 35103413
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Papain-Like Protease Potential Inhibitors-In Silico Quantitative Assessment.
Stasiulewicz A; Maksymiuk AW; Nguyen ML; Bełza B; Sulkowska JI
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921228
[TBL] [Abstract][Full Text] [Related]
19. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel human USP2 inhibitor and its putative role in treatment of COVID-19 by inhibiting SARS-CoV-2 papain-like (PLpro) protease.
Mirza MU; Ahmad S; Abdullah I; Froeyen M
Comput Biol Chem; 2020 Dec; 89():107376. PubMed ID: 32979815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
